Literature DB >> 19060849

FDA launches priority vouchers for neglected-disease drugs.

Emily Waltz.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 19060849     DOI： 10.1038/nbt1208-1315

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  5 in total

1.  AbbVie buys last available priority voucher for $350 million.

Authors:  Chris Morrison
Journal:  Nat Biotechnol       Date:  2015-11       Impact factor: 54.908

2.  Combined insulin/GLP-1 pens near market.

Authors:  Eva von Schaper
Journal:  Nat Biotechnol       Date:  2016-09-08       Impact factor: 54.908

3.  Spanish group defeats Shkreli in Chagas voucher race.

Authors:  Lisa Melton
Journal:  Nat Biotechnol       Date:  2017-11-09       Impact factor: 54.908

4.  Phosphodiesterase inhibitors as a new generation of antiprotozoan drugs: exploiting the benefit of enzymes that are highly conserved between host and parasite.

Authors:  Thomas Seebeck; Geert Jan Sterk; Hengming Ke
Journal:  Future Med Chem       Date:  2011-08       Impact factor: 3.808

5.  Fostering Canadian drug research and development for neglected tropical diseases.

Authors:  Patricia Gabriel; Rebecca Goulding; Cecily Morgan-Jonker; Shannon Turvey; Jason Nickerson
Journal:  Open Med       Date:  2010-05-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.